Anti-EGFR antibody and use thereof

摘要

A cell growth inhibitor that includes, as an antibody component, an artificially produced anti-EGFR antibody having specific binding capacity to EGFR which is characterized in that an epitope therefor is in a cysteine-rich subdomain 2 (C2 domain) and/or in a ligand-binding domain 1 (L1 domain) among four subdomains contained in the extracellular domain of EGFR.

主权项

1. A composition comprising:
(1) a pharmaceutically acceptable carrier; and (2) an active ingredient capable of suppressing growth of at least one epidermal growth factor receptor (EGFR)-expressing cell, the active ingredient comprising either or both of
(A) an anti-EGFR antibody having specific binding capacity to EGFR, including:a heavy chain variable region (VH region) having the amino acid sequence of SEQ ID NO: 1, anda light chain variable region (VL region) having the amino acid sequence of SEQ ID NO: 2, wherein:the anti-EGFR antibody has specific binding capacity to an epitope of EGFR,the epitope is in a cysteine-rich subdomain 2 (C2) being a fourth subdomain from a N-terminal of an extracellular domain among four subdomains contained in EGFR; and(B) an anti-EGFR antibody having specific binding capacity to EGFR, including:a heavy chain variable region (VH region) having the amino acid sequence of SEQ ID NO: 3, anda light chain variable region (VL region) having an-the amino acid sequence of SEQ ID NO: 4, wherein:the anti-EGFR antibody has specific binding capacity to an epitope of EGFR,the epitope is in a ligand-binding domain 1 (L1) being a first subdomain from a N-terminal of an extracellular domain among four subdomains contained in EGFR.